Please use this identifier to cite or link to this item:
Title: The prognostic value of high sensitivity C-reactive protein in a multi-ethnic population after >10 years of follow-up: The Multi-Ethnic Study of Atherosclerosis (MESA)
Author: Cainzos Achirica, Miguel
Miedema, Michael D.
McEvoy, John W.
Cushman, Mary
Dardari, Zeina
Greenland, Philip
Nasir, Khurram
Budoff, Matthew J.
Al-Mallah, Mouaz H.
Yeboah, Joseph
Blumenthal, Roger S.
Comín Colet, Josep
Blaha, Michael J.
Keywords: Malalties arterials
Malalties cardiovasculars
Pronòstic mèdic
Arteries Diseases
Cardiovascular diseases
Issue Date: 1-Aug-2018
Publisher: Elsevier B.V.
Abstract: Background: The prognostic value of hsCRP in contemporary multi-ethnic populations is unclear, particularly in statin users. The aim of this study was to characterize the prognostic utility of hsCRP for atherosclerotic CVD (ASCVD) risk prediction in a multi-ethnic population including non-users and users of statins followed for >13 years. Associations with heart failure (HF), atrial fibrillation (AF), venous thromboembolism (VTE), cancer, and all-cause death were also examined. Methods and results: We evaluated 6757 participants from the Multi-Ethnic Study of Atherosclerosis (MESA; 1002 using statins at baseline), median follow-up 13.2 years. Higher levels of hsCRP were associated with a higher risk of all study endpoints in the unadjusted Cox Proportional Hazards regression analyses, except AF. Among non-users of statins, hsCRP only remained associated with VTE after adjusting for ASCVD risk factors, and did not improve risk prediction. Among users of statins, hsCRP did not improve ASCVD risk prediction either, although it was strongly associated with incident HF (HR for hsCRP ≥ 2 vs <2 mg/L 3.99; 95% CI 2.02, 7.90) and all-cause death (HR 1.52; 95% CI 1.11, 2.08) in multivariable analyses, and hsCRP significantly improved prediction of HF (area under the curve [AUC] basic model 0.741, AUC basic + hsCRP 0.788). Conclusions: The utility of hsCRP for ASCVD prediction was modest. On the other hand, hsCRP was associated with incident VTE in statin non-users, and all-cause mortality and HF in statin users. In the latter, hsCRP improved the prediction of incident HF events. This finding should be replicated in larger cohorts.
Note: Versió postprint del document publicat a:
It is part of: International Journal of Cardiology, 2018, vol. 264, p. 158-164
Related resource:
ISSN: 0167-5273
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Ciències Clíniques)

Files in This Item:
File Description SizeFormat 
702593.pdf411.67 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons